Teva-Pregabalin controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
Teva Canada recalls two lots of Teva-Pregabalin 150 mg capsules due to sertraline cross-contamination
Recall announced
Teva Canada Ltd. recalled two lots of Teva-Pregabalin 150 mg capsules (DIN 02361205, lots 100070495 and 100068913, expiry July 31, 2027) after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis. Health Canada is monitoring the company's recall and implementation of corrective and preventive actions.
Teva Canada Ltd. is recalling two lots of Teva-Pregabalin 150 mg capsules (DIN 02361205, lots 100070495 and 100068913, expiry July 31, 2027) after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis. Health Canada is monitoring the company's recall and implementation of corrective and preventive actions.
Company response
Recall — Teva Canada Ltd.
Remediation — Teva Canada Ltd.
Health Canada is monitoring the company’s recall and implementation of corrective and preventive actions.
Source excerpt
Health Canada is monitoring the company’s recall and implementation of corrective and preventive actions.